Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Ashwani Verma
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 15on tracked calls
- Challenge rate
- 20%3 of 15 questions
- Companies
- 3questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 15 of 15 questions from 3 companies
VTRSViatris10 questions · 7 reporting periods · 3 of 10 challenging
Calendar 2026 Q2
at the midpoint of 2026 guide, you're raising revenue by $50 million, but EBITDA by $100 million.
Show response
Paul gave e-commerce mix (10-15% of China) and explained EBITDA outpaced revenue on cost-containment measures ahead of schedule; direct.
Calendar 2026 Q1
just trying to get a sense of how soon can we get there at the 4% run rate
Show response
Scott confirmed 4% organic growth target by 2030. Starting with 3% in Q1 2026 is a strong start. Expects growth to ramp through 2027-2029 from launches, clinical readouts, and BD-sourced growth assets. Significant cash available to supplement organic growth.
Calendar 2025 Q4
You are effectively spending $700–$850 pre-tax charges for a $400 million net savings. Is this within typical benchmark range
Show response
Doretta broke down the $700M+: approximately $250M one-time restructuring costs, $110M Biocon tax costs, and $320M divestiture-related cash/costs/taxes. Corinne said meloxicam will initially target post-operative settings with specialty sales force focused on surgeons, orthopedists, dental, podiatrists.
Calendar 2025 Q3
is that the right way to think about how you spend it out as in thre's more potential for savings from commercial, followed by R&D and then COGS
Show response
Scott identified sourcing/manufacturing/supply chain as largest savings potential, followed by corporate support. Doretta noted 2026 pushes: continued commercial strength, new products; pulls: North America competition, Amitiza LOE in Japan.
Calendar 2025 Q2
on the enterprise-wide strategic review, still waiting to hear a little bit of clarity in terms of what is the scope of activities that you want to showcase and what's the time line for that
Show response
Scott confirmed significant cost savings expected from the enterprise review. Looking at organizational structure post-merger and post-divestiture. Plans to provide significant granularity at the Q3 call in November.
I wanted to ask about the China business. It seems particularly strong this quarter. I know you called out some purchasing patterns. What's the growth excluding that
Show response
Corinne attributed 9% China growth to diversified commercial model and customer buying pattern timing. Growth expected to moderate to low to mid-single digits in second half. Approximately 95% of brands through BBP process.
Calendar 2025 Q1
Is there more appetite here to go up substantially on the repo given where the stock is
Show response
Scott confirmed potential to exceed $650M but wants strategic flexibility given tariff uncertainty. Doretta noted $1.7B deployable cash flow unchanged.
can you help us understand how fast acting is this? For example, how quickly does this get static benefit in terms of hours
Show response
Philippe cited 95 minutes for 2-point NPI reduction vs 338 minutes for placebo. Would not speculate on whether FDA would grant a fast-acting label claim.
Calendar 2024 Q4
the stock is trading sort of mid-teens down in pre-market. Why not be even more aggressive on the buyback here
Show response
Scott confirmed $500-650M is a minimum, will increase buybacks if stock remains under pressure while balancing with BD opportunities.
typically these type of warning letters can take a minimum of two years to dissolve
Show response
Scott addressed lenalidomide specifically, noting the economics were set to diminish 10-12 months later anyway, but did not fully address the two-year warning letter timeline.
INCYIncyte3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2026 Q1
how do you think that plays out? Like could this be a challenge if you have to titrate patients and some don't get the benefit of the efficacy
Show response
Pablo clarified most patients normalize platelets at 750mg starting dose, supporting primary endpoint achievement at 24 weeks. Step-up to 2,500mg covers heterogeneity in less sensitive patients. Study designed to achieve durable CHR across all mutation types.
Calendar 2025 Q3
at this point, are you able to pursue first-line or naive patients in registrational studies
Show response
Pablo confirmed full intent to develop 989 for first-line MF with clear preclinical synergy data between 989 and ruxolitinib. Goal is at-home self-administered subcu device via Enable collaboration, targeting 2026 deployment.
Calendar 2025 Q1
Just if you can share what are your expectations, here in these studies in terms of, the efficacy that would be great
Show response
Steven expressed growing confidence in CD19 antibody profile. Noted CD19 expression maintained after treatment, allowing subsequent CAR-T. Event-driven study nearing required events threshold.
INSMInsmed Incorporated2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q1
Can you confirm the 1Q BRINSUPRI gross to net that you mentioned? Is it at the top end of the range, the mid-20s to low 30s?
Show response
CFO confirmed Q1 gross-to-net was within the guided mid-20s to low-30s range but declined to specify where within the range. Same for ARIKAYCE at low to mid-20s.
Calendar 2025 Q3
do you have this data in-house already just realizing that the primary completion was also August
Show response
CMO confirmed vast majority of data in-house and in cleaning process, with some final patient data still coming in. Database lock and cleaning to meet highest regulatory standards. CEO noted early January timing avoids disrupting holidays.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VTRS Viatris | 10 | 30%3 of 10 questions |
| INCY Incyte | 3 | 0%none of 3 questions |
| INSM Insmed Incorporated | 2 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 100%2 of 2 questions | 1 |
| 2025 Q1 | 3 | 0%none of 3 questions | 2 |
| 2025 Q2 | 2 | 0%none of 2 questions | 1 |
| 2025 Q3 | 3 | 0%none of 3 questions | 3 |
| 2025 Q4 | 1 | 100%1 of 1 question | 1 |
| 2026 Q1 | 3 | 0%none of 3 questions | 3 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q42 questions · challenge rate 100% (2 of 2 questions) · 1 company
- 2025 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 3 companies
- 2025 Q41 question · challenge rate 100% (1 of 1 question) · 1 company
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 3 companies
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D5
- Revenue Growth4
- Cost Pressure3
- Product Launch2
- Capital Allocation2
- Guidance Reliability1
- Geographic Expansion1
- Margin1
- Pricing1
- Competitive Dynamics1
Show all 11 topics
- Regulation Policy1